MRKMerck & Co., Inc.SEC EDGAR
Use with Claude or ChatGPT
  • Overview
  • Income statement
  • Balance sheet
  • Cash flow
  • Earnings

Merck & Co., Inc. (MRK) Earnings history

8 quarters held2/7 transcripts analyzed3/40 figures attested
Ask your agent: get_earnings
PeriodRevenueYoYNet incomeEPS (dil.)Filed
Q3 2026$18.1B+4.7%$5.1B$2.04Oct 29, 2026
LATESTEarnings filing (8-K)10-QFiled Oct 29, 2026, 6:43 AM ET
Earnings call · Oct 29, 2026deckdeck
Q3 FY26YoY
Revenue$18.1B+4.7%
Net income$5.1B-12.4%
Op income––
EPS (dil.)$2.041-12.1%
EPS (basic)––
Gross margin72.9%-4.8pp
Net margin28.0%-5.5pp
  1. [1] “For the third quarter of 2026, Generally Accepted Accounting Principles (GAAP) earnings per share (EPS) assuming dilution was $2.04” view source

Guidance & outlook

Management guidance

Q3 2026

fy_current

revenue
$66.8B—$67.3B
other
32—33
eps_diluted
$2.77—$2.82

Special items & operational metrics

Operational metrics

Q3 2026

LLM-extracted from the earnings release; unverified.

Metric Name
N/A
null
Q2 2026$16.6B+5.1%$-1.3B$-0.54Aug 4, 2026
Earnings filing (8-K)10-QFiled Aug 4, 2026, 6:47 AM ET
Earnings call · Aug 4, 2026deck
Q2 FY26YoY6M FY26
Revenue$16.6B+5.1%$32.9B
Net income$-1.3B-130.2%$-5.6B
Op income–––
EPS (dil.)$-0.541-130.7%–
EPS (basic)–––
Gross margin73.5%-4.0pp
Net margin-8.0%-36.0pp
  1. [1] “GAAP) loss / earnings per share (EPS) assuming dilution was a loss per share of $0.54” view source
Q1 2026$16.3B+4.9%$-4.2B$-1.72Apr 30, 2026
Earnings filing (8-K)10-QFiled Apr 30, 2026, 6:53 AM ET
Earnings call · Apr 30, 2026transcriptView originalprepared remarksQ&Adeck
Q1 FY26YoY
Revenue$16.3B1+4.9%
Net income$-4.2B-183.5%
Op income––
EPS (dil.)$-1.72-185.6%
EPS (basic)––
Gross margin74.2%-3.8pp
Net margin-26.0%-58.7pp
  1. [1] “Total Worldwide Sales Were $16.3 Billion (5% Growth; 3% Growth ex-FX)” view source
Q4 2025$16.4B+5.0%$3.0B$1.19Feb 3, 2026
Earnings filing (8-K)10-KFiled Feb 3, 2026, 6:38 AM ET
Earnings call · Feb 3, 2026transcriptView originalprepared remarksQ&Adeck
Q4 FY25YoYFY25
Revenue$16.4B+5.0%$65.0B
Net income$3.0B-20.8%$18.3B
Op income–––
EPS (dil.)$1.19-20.3%–
EPS (basic)–––
Gross margin66.2%-9.3pp
Net margin18.1%-5.9pp
Q3 2025$17.3B+4.0%$5.8B$2.32Oct 30, 2025
Earnings filing (8-K)10-QFiled Oct 30, 2025, 6:40 AM ET
Q3 FY25YoY9M FY25
Revenue$17.3B+4.0%–
Net income$5.8B+83.0%$15.3B
Op income–––
EPS (dil.)$2.32+87.0%$6.08
EPS (basic)–––
Gross margin77.7%+2.2pp
Q2 2025$15.8B-2.0%$4.4B$1.76Jul 29, 2025
Earnings filing (8-K)10-QFiled Jul 29, 2025, 6:42 AM ET
Q2 FY25YoY6M FY25
Revenue$15.8B-2.0%–
Net income$4.4B-19.0%$9.5B
Op income–––
EPS (dil.)$1.76-17.8%$3.77
EPS (basic)–––
Gross margin77.5%+0.7pp
Q1 2025$15.5B-1.6%$5.1B$2.01Apr 24, 2025
Earnings filing (8-K)10-QFiled Apr 24, 2025, 6:45 AM ET
Q1 FY25YoY
Revenue$15.5B-1.6%
Net income$5.1B+6.7%
Op income––
EPS (dil.)$2.01+7.5%
EPS (basic)––
Gross margin78.0%+0.4pp
Q4 2024$15.6B+6.8%$3.7B$1.48Feb 4, 2025
Earnings filing (8-K)10-KFiled Feb 4, 2025, 6:45 AM ET
Q4 FY24YoYFY24
Revenue$15.6B+6.8%$64.2B
Net income$3.7B–$17.1B
Op income–––
EPS (dil.)$1.48–$6.74
EPS (basic)–––
Gross margin75.5%+2.2pp

IR event calendar

The IR event calendar could not be fetched at last check (error); events may exist at the source but weren't retrievable.

The IR event calendar could not be fetched at last check (error); events may exist at the source but weren't retrievable.

Filing coverage

54 filings indexed · 104,201 XBRL facts
FilingDatePeriodSectionsTables
10-Q2026-11-04–3044
8-K2026-10-29Q3 202690
8-K2026-10-13–30
10-Q2026-08-07–3149
8-K2026-08-04–90
8-K2026-05-28–10
8-K2026-05-22–10
10-Q2026-05-04–3055
8-K2026-04-30–90
DEF 14A2026-04-08–200

Showing the latest 10 of 54 — the full set is in the API.

Related Research

Analysis

The $15 Billion Earnings Illusion Inside AbbVie's 10-K

Analysis

Boston Scientific Hit a ROIC Inflection — Then Bet $14.5B on Penumbra

Analysis

The $1.7B Hidden Cost of Stryker's Acquisition Machine